One shot of an RSV vaccine protects adults ages 60 or older from RSV-associated hospitalization and demanding sickness throughout two consecutive RSV seasons.
RT’s Three Key Takeaways:
- Robust safety in opposition to RSV hospitalization — A single RSV vaccine dose diminished hospitalization threat by 58% in adults 60+ over two consecutive RSV seasons, with the best safety (69%) within the first 12 months.
- Waning effectiveness over time — Safety declined to 48% within the second 12 months, suggesting that booster doses could also be wanted to maintain long-term advantages.
- Helps present vaccine steerage — Findings reinforce CDC suggestions for RSV vaccination in older adults, significantly these 75+ or aged 50–74 at elevated threat of extreme RSV.
One shot of an RSV vaccine protects adults ages 60 or older from RSV-associated hospitalization and demanding sickness throughout two consecutive RSV seasons, in response to a research revealed in JAMA by the IVY Community analysis group.
RSV causes substantial seasonal sickness throughout fall and winter within the US, with an estimated 100,000-150,000 hospitalizations and 4,000-8,000 deaths occurring yearly amongst adults 60 or older.
The outcomes reinforce the suggestions for RSV vaccines in older adults and lay the groundwork for understanding how lengthy a single dose of the vaccine could also be efficient, in response to Wesley Self, MD, MPH, principal investigator for the IVY Community and Senior Vice President for Medical Analysis at Vanderbilt College Medical Heart.
“These outcomes clearly display that the RSV vaccines stop hospitalizations and demanding sickness because of RSV an infection amongst older People,” Self mentioned. “It’s thrilling to see the general public well being advantages of this new vaccination program.”
Investigators used information from a multicenter hospital community often called the IVY Community (The Investigating Respiratory Viruses within the Acutely Sick Community) to evaluate RSV vaccine effectiveness. They used a test-negative, case-control research design amongst 6,958 individuals 60 years or older who had been hospitalized with acute respiratory sickness at one in all 26 hospitals in 20 US states throughout two RSV seasons from October 1, 2023–March 31, 2024 and October 1, 2024–April 30, 2025.
General, vaccination diminished the chance of RSV hospitalization by 58% throughout two RSV seasons, together with 69% within the first 12 months after vaccination and 48% within the second 12 months after vaccination.
“Our information present that the helpful results of RSV vaccines seem to wane over time,” Self mentioned. “Redosing the vaccine at some interval after the preliminary dose may very well be a technique to take care of safety over longer intervals of time. Will probably be essential to proceed to carefully monitor vaccine effectiveness over time to know how lengthy the profit lasts after a single dose and if repeat dosing must be thought-about.”
Present RSV vaccine suggestions are for all adults aged 75 years and older and people aged 50-74 years who’re at an elevated threat of extreme RSV.
